# US 11,078,255 B2 · Ca2+ regulated binding agents > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,078,255 B2 - Document ID: US11078255B2 - Status: Granted - Kind: B2 - Application number: 16/550,803 - Filed: 2019-08-26 - Published: 2020-02-27 - Granted: 2021-08-03 - Earliest claimed: 2018-08-24 - Assignees: Symthera Canada Ltd. - Applicants: Symthera Canada Ltd. - Inventors: Chai Ezerzer - Web page: https://patentgrep.com/patent/US11078255B2 ## CPC - C07K 14/71: for growth factors; for growth regulators - C07K 14/47: from mammals - C07K 14/4728: {Calcium binding proteins, e.g. calmodulin} - C07K 14/485: Epidermal growth factor [EGF], i.e. urogastrone - G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors} - C07K 2319/00: Fusion polypeptide - C07K 2319/20: containing a tag with affinity for a non-protein ligand - C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies - C07K 2319/74: containing a fusion for binding to a cell surface receptor - G01N 2333/4727: Calcium binding proteins, e.g. calmodulin - G01N 2333/485: Epidermal growth factor [EGF] (urogastrone) - G01N 2333/49: Platelet-derived growth factor [PDGF] - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract Disclosed are binding agents that include (a) a calcium binding portion which includes an F-helix peptide and a calcium binding loop peptide derived from an EF-hand motif of a calcium binding protein, wherein the C-terminus of the F-helix peptide is covalently linked to the N-terminus of the calcium binding loop peptide by a peptide bond, and (b) a targeting peptide, wherein the N-terminus of the targeting peptide is covalently linked to the C-terminus of the calcium binding portion by a peptide bond. The binding agents can be used for diagnosis and treatment of various disorders. ## Claims ### Claim 1 A binding agent comprising: (a) a calcium binding portion; and (b) a targeting peptide, wherein the N-terminus of the targeting peptide is covalently linked to the C-terminus of the calcium binding portion by a peptide bond; wherein the calcium binding portion is selected from the group consisting of one or more of SEQ ID NOS. 68-96, and wherein the targeting peptide is selected from the group consisting of one or more of SEQ ID NOS. 1-10. ### Claim 2 (depends on 1) A method of determining the presence of an epidermal growth factor receptor (EGFR) family member in a sample, said method comprising: (a) providing a sample obtained from a subject, (b) contacting the sample with the binding agent of claim 1, the binding agent comprising a targeting peptide selected from SEQ ID Nos. 1, 3, 5, 6, and 7 that binds to an epidermal growth factor receptor family member protein, and (c) detecting the presence of a bound complex comprising the binding agent and the EGFR family member wherein the presence of the bound complex indicates the presence of the EGFR family member in the sample. ### Claim 3 (depends on 2) The method of claim 2, wherein the amount of the EGFR family member in the sample is determined according to an amount of the bound complex detected in (c). ### Claim 4 (depends on 1) A method of determining the presence of a platelet derived growth factor receptor (PDGFR) family member in a sample, said method comprising: (a) providing a sample obtained from a subject, (b) contacting the sample with the binding agent of claim 1, the binding agent comprising a targeting peptide selected from SEQ ID Nos. 2-4, and 7-10 that binds to a platelet derived growth factor receptor family member protein, and (c) detecting the presence of a bound complex comprising the binding agent and the PDGFR family member wherein the presence of the bound complex indicates the presence of the PDGFR family member in the sample. ### Claim 5 (depends on 4) The method of claim 4, wherein the amount of the PDGFR family member in the sample is determined according to an amount of the bound complex detected in (c). ### Claim 6 (depends on 2) The method of claim 2, further comprising contacting the sample with calcium prior to (c), wherein a final concentration of calcium in the sample is within the range from about 0.01 mM to about 500 mM. ### Claim 7 (depends on 4) The method of claim 4, further comprising contacting the sample with calcium prior to (c), wherein a final concentration of calcium in the sample is within the range from about 0.01 mM to about 500 mM.